Olanzapine Hydrochloride
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jun 1, 2004 → Nov 1, 2004
NCT ID
NCT00485810About Olanzapine Hydrochloride
Olanzapine Hydrochloride is a phase 1/2 stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00485810. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00485810 | Phase 1/2 | Completed |
| NCT00485823 | Approved | Completed |
Competing Products
20 competing products in Schizophrenia